Guillermo Lendínez‐Cano

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.

Xavier García del Muro, Begoña P. Valderrama, Ana Medina et al. · Journal of Clinical Oncology · 2021 · 34 citations

Medicine, Oncology, Urology +17

Prospective study of diagnostic accuracy in the detection of high‐grade prostate cancer in biopsy‐naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test

Guillermo Lendínez‐Cano, Enrique Gómez‐Gómez, P. Morales Jiménez et al. · The Prostate · 2021 · 28 citations

Medicine, Oncology, Urology +17

Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

Steven MacLennan, Nuno Pereira‐Azevedo, Eilidh Duncan et al. · European Urology · 2023 · 19 citations · Full text

Medicine, Surgery, Urology +15

Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial

Xavier García del Muro, Begoña P. Valderrama, Ana Medina et al. · Clinical Cancer Research · 2025 · 14 citations

Medicine, Oncology, Radiation Oncology +17

Comparison of pathological data between prostate biopsy and radical prostatectomy specimen in patients with low to very low risk prostate cancer

Guillermo Lendínez‐Cano, J. Alonso-Flores, V. Beltrán-Aguilar et al. · Actas Urológicas Españolas (English Edition) · 2015 · 13 citations

Medicine, Pathology, Urology +16